A Performance Study of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for Fluorescence-guided Imaging to Determine Local Extent and Resectability During Surgical Resection of Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment
Latest Information Update: 10 Apr 2024
At a glance
- Drugs SGM 101 (Primary)
- Indications Adenocarcinoma; Pancreatic ductal carcinoma
- Focus Diagnostic use
- Acronyms FLUOPANC-II
Most Recent Events
- 03 Apr 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2026.
- 03 Apr 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2026.
- 03 Apr 2024 Status changed from not yet recruiting to recruiting.